3263-001: A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations
Clinical Trial Grant
Awarded By
Alterome Therapeutics, Inc.
Start Date
April 7, 2026
End Date
April 21, 2031
Awarded By
Alterome Therapeutics, Inc.
Start Date
April 7, 2026
End Date
April 21, 2031